Riversnorman8394

All the resections were complete. Prosthetic reconstruction was in 4 cases. Mean operative time was 130±25.6 minutes; mean vascular clamping time was 28.2±3.2 minutes. No mortality occurred. Major complication rate was 11.1 %. At a mean follow-up of 17±9 months (range 5-29) recurrence rate was 33.3%. LC-2 Median survival was 20 months.

Direct cross-clamping as an alternative to CPB for resection of lung cancer infiltrating the aortic arch or the subclavian artery is a feasible, safe and reliable procedure in selected patients.

Direct cross-clamping as an alternative to CPB for resection of lung cancer infiltrating the aortic arch or the subclavian artery is a feasible, safe and reliable procedure in selected patients.

Tumor response and lymph node involvement are the most important prognosticators in resected patients with esophageal adenocarcinoma after neoadjuvant chemoradiation (nCRT). We hypothesise that lymph node response (LNR) is also a valuable prognosticator in these patients, potentially revealing the added effect of nCRT.

Hematoxylin-eosin slides of 193 esophageal adenocarcinoma patients with clinical suspicion of lymph node involvement (cN+) and treated with nCRT between 2008 and 2015 were assessed. Lymph nodes containing viable tumor cells were considered ypN+ and those negative for viable tumor were ypN0. LNR was also described according to an earlier defined method. Three groups were obtained ypN0/LNR-, ypN0/LNR+ and ypN+. They were compared to 188 cN+ patients being pN0 (n=45) or pN+ (n=143) after upfront esophageal resection.

44 patients were ypN0/LNR-, 55 ypN0/LNR+ and 94 ypN+. Median overall survival was respectively 96.4, 31.2 and 20.6 months and was significantly different between ypN0/LNR- and y to pN+ patients.We admitted a 76-year-old woman for treatment of an ascending aortic aneurysm with left ventricular outflow tract (LVOT) obstruction and systolic anterior motion (SAM) of the mitral valve. Echocardiography showed an elevated velocity of the LVOT flow with a sigmoid septum. Mild mitral regurgitation was also detected due to SAM. We performed a graft replacement of the ascending aorta, following which the LVOT obstruction and SAM were resolved. This is the first reported case in which the traction of a graft likely released the compression on the aortic root and ventricular septum.

The value of neoadjuvant treatment in combination with resection as multimodality therapy (MMT) for Stage IIB non-small cell lung cancer (NSCLC) remains controversial.

This is a national cohort study of clinical stage IIB NSCLC patients (2006-2015) using the National Cancer Database (NCDB). Cohorts were defined based on the MMT sequence and were categorized as surgery plus adjuvant chemotherapy (AC), surgery plus adjuvant chemoradiation (ACRT), neoadjuvant therapy plus surgery (NA), surgery-alone, and definitive chemotherapy or chemoradiation (non-surgical). The primary comparison was between NA and AC cohorts. Propensity matching methods were employed to match cohorts who received AC versus NA. Multivariable Cox regression was used to analyze the difference in risk of death between NA and AC.

There were 10,841 patients with Stage IIB lung cancer 2,476 AC, 854 ACRT, 1,195 NA, 2,019 surgery-alone, and 4,297 non-surgical. Of the 6,544 patients who received surgery, 37.8% received AC, 13.1% received ACRT, 18.3% received NA and 30.9% received surgery alone. Relative to those treated with AC, non-surgical treatment (HR 2.92; 95%CI 2.69-3.17) or surgery-alone (HR 1.26; 95%CI 1.14-1.38) were associated significantly higher risk of death. After propensity matching, there was no difference in risk of death between NA and AC (HR 1.07; 95%CI 0.88-1.31).

MMT, including surgical resection, is associated with improved OS, regardless of treatment sequence with no difference in survival based on a NA or AC approach. The potential benefits of NA over AC to ensure patients complete MMT warrants further prospective investigation.

MMT, including surgical resection, is associated with improved OS, regardless of treatment sequence with no difference in survival based on a NA or AC approach. The potential benefits of NA over AC to ensure patients complete MMT warrants further prospective investigation.The coronavirus disease 2019 (COVID-19) is caused by a novel coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is associated with several fatal cases worldwide. The rapid spread of this pathogen and the increasing number of cases highlight the urgent development of vaccines. Among the technologies available for vaccine development, DNA vaccination is a promising alternative to conventional vaccines. Since its discovery in the 1990s, it has been of great interest because of its ability to elicit both humoral and cellular immune responses while showing relevant advantages regarding producibility, stability, and storage. This review aimed to summarize the current knowledge and advancements on DNA vaccines against COVID-19, particularly those in clinical trials.

We investigated the therapeutic effects of losartan, an angiotensin II type 1 receptor blocker, on prostatic hyperplasia in spontaneously hypertensive rats (SHRs).

Male SHRs (age, 36weeks) were perorally treated with losartan (3 or 10mg·kg

) or vehicle once daily for 18weeks. Age-matched Wistar Kyoto rats (WKYs) were used as vehicle-treated controls (n=8). The effects of losartan were evaluated by analyzing prostate weight, blood pressure, and prostatic blood flow. The tissue malondialdehyde (MDA), interleukin-6 (IL-6), and basic fibroblast growth factor (bFGF) levels were measured. Histological analysis for the ventral prostate involved hematoxylin and eosin staining and TdT-mediated dUTP nick-end labeling (TUNEL) assay.

Compared to the vehicle-treated WKYs, the vehicle-treated SHRs had significantly higher prostate weight, prostate weight/body weight ratio (PBR), blood pressure, glandular epithelial area, and tissue MDA, IL-6, and bFGF levels in the ventral prostate and lower prostatic blood flow. Treatment with losartan caused significant recovery of blood flow and decreased PBR and glandular epithelial area as well as tissue MDA, IL-6, and bFGF levels in the SHR ventral prostate without affecting blood pressure. High-dose losartan significantly decreased blood pressure and increased TUNEL-positive cells in the ventral prostate in SHRs.

Chronic losartan treatment could ameliorate prostatic hyperplasia via recovery of reduced prostatic blood flow and induction of apoptosis in the ventral prostate in SHRs. Losartan might have therapeutic effects on not only hypertension but also prostatic hyperplasia in humans.

Chronic losartan treatment could ameliorate prostatic hyperplasia via recovery of reduced prostatic blood flow and induction of apoptosis in the ventral prostate in SHRs. Losartan might have therapeutic effects on not only hypertension but also prostatic hyperplasia in humans.